Picture loading failed.

Anti-EGFR therapeutic antibody (Pre-made Futuximab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Futuximab (992 DS) (INN) is a chimeric monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and also binds to HER1.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-227-1mg 1mg 3090
GMP-Bios-ab-227-10mg 10mg 21890
GMP-Bios-ab-227-100mg 100mg 148000
GMP-Bios-ab-227-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-EGFR therapeutic antibody (Pre-made Futuximab biosimilar,Whole mAb)
INN Name Futuximab
TargetEGFR
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesSymphogen;Merck
Conditions Approvedna
Conditions ActiveColorectal cancer;Glioma;Non-small cell lung cancer
Conditions DiscontinuedHead and neck cancer;Oesophageal cancer
Development Techna